In conclusion, this retrospective study revealed that high plasma sPD-L1 levels were associated with poor response to EGFR-TKIs and that this finding could be a promising biomarker in patients with EGFR-mutant advanced NSCLC. Here, SPDL1 is linked to non-small cell lung carcinoma.